Ian M Anderson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8237139/publications.pdf

Version: 2024-02-01

159	12,097	31976	27406
papers	citations	53 h-index	106 g-index

167	167	167	11760
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective Disorders, 2000, 58, 19-36.	4.1	845
2	Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2005, 19, 567-596.	4.0	537
3	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 2015, 29, 459-525.	4.0	528
4	Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2014, 28, 403-439.	4.0	511
5	Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. British Journal of Psychiatry, 2002, 180, 396-404.	2.8	510
6	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 2008, 22, 343-396.	4.0	437
7	Magnetic resonance imaging studies in unipolar depression: Systematic review and meta-regression analyses. European Neuropsychopharmacology, 2012, 22, 1-16.	0.7	435
8	Systematic Review and Guide to Selection of Selective Serotonin Reuptake Inhibitors. Drugs, 1999, 57, 507-533.	10.9	406
9	Effects of lesions of the orbitofrontal cortex on sensitivity to delayed and probabilistic reinforcement. Psychopharmacology, 2002, 160, 290-298.	3.1	353
10	Meta-analytical studies on new antidepressants. British Medical Bulletin, 2001, 57, 161-178.	6.9	326
11	Affective Cognition and its Disruption in Mood Disorders. Neuropsychopharmacology, 2011, 36, 153-182.	5.4	264
12	State-dependent changes in hippocampal grey matter in depression. Molecular Psychiatry, 2013, 18, 1265-1272.	7.9	257
13	The Effect of Citalopram Pretreatment on Neuronal Responses to Neuropsychological Tasks in Normal Volunteers: An fMRI Study. Neuropsychopharmacology, 2005, 30, 1724-1734.	5.4	250
14	Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. Molecular Psychiatry, 2018, 23, 133-142.	7.9	247
15	The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. Journal of Psychopharmacology, 1994, 8, 238-249.	4.0	244
16	The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature. Journal of Affective Disorders, 2019, 242, 195-210.	4.1	206
17	Bipolar disorder. BMJ, The, 2012, 345, e8508-e8508.	6.0	173
18	Increased Amygdala Responses to Sad But Not Fearful Faces in Major Depression: Relation to Mood State and Pharmacological Treatment. American Journal of Psychiatry, 2012, 169, 841-850.	7.2	163

#	Article	IF	Citations
19	The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients. Journal of Affective Disorders, 2009, 118, 87-93.	4.1	160
20	Dieting reduces plasma tryptophan and alters brain 5-HT function in women. Psychological Medicine, 1990, 20, 785-791.	4.5	156
21	Relationship between 5-HT function and impulsivity and aggression in male offenders with personality disorders. British Journal of Psychiatry, 2001, 178, 352-359.	2.8	156
22	CNR1 Gene is Associated with High Neuroticism and Low Agreeableness and Interacts with Recent Negative Life Events to Predict Current Depressive Symptoms. Neuropsychopharmacology, 2009, 34, 2019-2027.	5.4	153
23	The CREB1-BDNF-NTRK2 Pathway in Depression: Multiple Gene-Cognition-Environment Interactions. Biological Psychiatry, 2011, 69, 762-771.	1.3	142
24	Temporal discounting in major depressive disorder. Psychological Medicine, 2014, 44, 1825-1834.	4.5	134
25	Neurobiological substrates of antisocial and borderline personality disorder: preliminary results of a functional fMRI study. Criminal Behaviour and Mental Health, 2004, 14, 39-54.	0.8	131
26	ECNP consensus meeting. Bipolar depression. Nice, March 2007. European Neuropsychopharmacology, 2008, 18, 535-549.	0.7	131
27	Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology, 2005, 180, 680-686.	3.1	121
28	Psychoeducation for relapse prevention in bipolar disorder: a systematic review of efficacy in randomized controlled trials. Bipolar Disorders, 2015, 17, 349-362.	1.9	121
29	Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study. NeuroReport, 2007, 18, 1351-1355.	1.2	118
30	State-dependent alteration in face emotion recognition in depression. British Journal of Psychiatry, 2011, 198, 302-308.	2.8	111
31	Effects of quinolinic acid-induced lesions of the orbital prefrontal cortex on inter-temporal choice: a quantitative analysis. Psychopharmacology, 2002, 165, 9-17.	3.1	100
32	Serotonergic modulation of neuronal responses to behavioural inhibition and reinforcing stimuli: an fMRI study in healthy volunteers. European Journal of Neuroscience, 2006, 23, 552-560.	2.6	99
33	Effects of orbital prefrontal cortex dopamine depletion on inter-temporal choice: a quantitative analysis. Psychopharmacology, 2004, 175, 206-14.	3.1	96
34	Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. British Journal of Psychiatry, 2000, 177, 292-302.	2.8	95
35	The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. Journal of Psychopharmacology, 2008, 22, 330-332.	4.0	93
36	Effect of acute tryptophan depletion on CO2-induced anxiety in patients with panic disorder and normal volunteers. British Journal of Psychiatry, 2000, 176, 182-188.	2.8	89

#	Article	IF	Citations
37	Recognising and managing antidepressant discontinuation symptoms. Advances in Psychiatric Treatment, 2007, 13, 447-457.	0.5	84
38	Brain galanin system genes interact with life stresses in depression-related phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1666-73.	7.1	83
39	Quantitative frontal and temporal structural MRI studies in personality-disordered offenders and control subjects. Psychiatry Research - Neuroimaging, 2002, 116, 133-149.	1.8	82
40	Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial. Lancet Psychiatry,the, 2017, 4, 365-377.	7.4	82
41	Attenuated responses to emotional expressions in women with generalized anxiety disorder. Psychological Medicine, 2011, 41, 1009-1018.	4.5	79
42	L-Tryptophan and prolactin release: Evidence for interaction between 5-HT1 and 5-HT2 receptors. Human Psychopharmacology, 1986, 1, 93-97.	1.5	78
43	The effects of real versus hypothetical reward on delay and probability discounting. Quarterly Journal of Experimental Psychology, 2010, 63, 1072-1084.	1.1	77
44	Assessing human 5-HT function in vivo with pharmacoMRI. Neuropharmacology, 2008, 55, 1029-1037.	4.1	75
45	Effects of quinolinic acid-induced lesions of the nucleus accumbens core on inter-temporal choice: a quantitative analysis. Psychopharmacology, 2007, 195, 71-84.	3.1	72
46	The Relationship between Serotonergic Function and the Psychopathy Checklist: Screening Version. Journal of Psychopharmacology, 2003, 17, 216-222.	4.0	70
47	Validation of the Mood Disorder Questionnaire for screening for bipolar disorder in a UK sample. Journal of Affective Disorders, 2008, 110, 180-184.	4.1	69
48	Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers. Psychopharmacology, 1992, 106, 428-432.	3.1	68
49	The effect of orbital prefrontal cortex lesions on performance on a progressive ratio schedule: implications for models of inter-temporal choice. Behavioural Brain Research, 2005, 156, 145-152.	2.2	68
50	Significant association between the C(â^'1019)G functional polymorphism of the HTR_{1A} gene and impulsivity. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 592-599.	1.7	62
51	Clomipramine enhances prolactin and growth hormone responses to l-tryptophan. Psychopharmacology, 1986, 89, 131-3.	3.1	61
52	The effects of gepirone on neuroendocrine function and temperature in humans. Psychopharmacology, 1990, 100, 498-503.	3.1	60
53	Regional default mode network connectivity in major depressive disorder: modulation by acute intravenous citalopram. Translational Psychiatry, 2019, 9, 116.	4.8	59
54	Neuronal correlates and serotonergic modulation of behavioural inhibition and reward in healthy and antisocial individuals. Journal of Psychiatric Research, 2010, 44, 123-131.	3.1	58

#	Article	IF	Citations
55	Reversed Frontotemporal Connectivity During Emotional Face Processing in Remitted Depression. Biological Psychiatry, 2012, 72, 604-611.	1.3	55
56	Role of the orbital prefrontal cortex in choice between delayed and uncertain reinforcers: a quantitative analysis. Behavioural Processes, 2003, 64, 239-250.	1.1	54
57	Variations in the cannabinoid receptor 1 gene predispose to migraine. Neuroscience Letters, 2009, 461, 116-120.	2.1	53
58	Diminished Neural and Cognitive Responses to Facial Expressions of Disgust in Patients with Psoriasis: A Functional Magnetic Resonance Imaging Study. Journal of Investigative Dermatology, 2009, 129, 2613-2619.	0.7	49
59	Effects of lesions of the nucleus accumbens core on inter-temporal choice: Further observations with an adjusting-delay procedure. Behavioural Brain Research, 2009, 202, 272-277.	2.2	48
60	The effect of acute citalopram on face emotion processing in remitted depression: A pharmacoMRI study. European Neuropsychopharmacology, 2011, 21, 140-148.	0.7	47
61	Interaction between a history of depression and rumination on neural response to emotional faces. Psychological Medicine, 2011, 41, 1845-1855.	4.5	47
62	Social-economical decision making in current and remitted major depression. Psychological Medicine, 2015, 45, 1301-1313.	4.5	46
63	Executive and memory function and its relationship to trait impulsivity and aggression in personality disordered offenders. Journal of Forensic Psychiatry Psychology, 2002, 13, 503-526.	0.3	45
64	Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). BMJ: British Medical Journal, 2018, 363, k4218.	2.3	44
65	Clinical trials of antidepressant medications are producing meaningless results. British Journal of Psychiatry, 2003, 183, 102-104.	2.8	43
66	Adjunctive fast repetitive transcranial magnetic stimulation in depression. British Journal of Psychiatry, 2007, 190, 533-534.	2.8	43
67	Decreased plasma tryptophan concentration in major depression: relationship to melancholia and weight loss. Journal of Affective Disorders, 1990, 20, 185-191.	4.1	42
68	d -Fenfluramine in panic disorder: a dual role for 5-hydroxytryptamine. Psychopharmacology, 2000, 149, 251-258.	3.1	42
69	5-HT modulation of pain perception in humans. Psychopharmacology, 2017, 234, 2929-2939.	3.1	40
70	Reduced Medial Prefrontal Responses to Social Interaction Images in Remitted Depression. Archives of General Psychiatry, 2012, 69, 37.	12.3	38
71	Neural correlates of choice behavior related to impulsivity and venturesomeness. Neuropsychologia, 2011, 49, 2311-2320.	1.6	37
72	Risk-Taking Behavior in a Gambling Task Associated with Variations in the Tryptophan Hydroxylase 2 Gene: Relevance to Psychiatric Disorders. Neuropsychopharmacology, 2010, 35, 1109-1119.	5.4	35

#	Article	IF	Citations
73	Effect of acute tryptophan depletion on the response to controllable and uncontrollable noise stress. Biological Psychiatry, 2005, 57, 295-300.	1.3	33
74	Effect of quinolinic acid-induced lesions of the nucleus accumbens core on performance on a progressive ratio schedule of reinforcement: implications for inter-temporal choice. Psychopharmacology, 2008, 197, 339-350.	3.1	33
75	The HTR1A and HTR1B receptor genes influence stress-related information processing. European Neuropsychopharmacology, 2011, 21, 129-139.	0.7	33
76	Effect of disconnecting the orbital prefrontal cortex from the nucleus accumbens core on inter-temporal choice behaviour: A quantitative analysis. Behavioural Brain Research, 2008, 191, 272-279.	2.2	31
77	Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. Lancet Psychiatry,the, 2016, 3, 117-127.	7.4	30
78	A survey of the teaching and assessment of undergraduate psychiatry in the medical schools of the United Kingdom and Ireland. Medical Teacher, 2009, 31, 1024-1029.	1.8	29
79	Effects of Different Stressors Are Modulated by Different Neurobiological Systems: The Role of GABA-A Versus CB1 Receptor Gene Variants in Anxiety and Depression. Frontiers in Cellular Neuroscience, 2019, 13, 138.	3.7	29
80	Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: An open-label, pilot study. Journal of Affective Disorders, 2009, 117, 116-119.	4.1	28
81	Choice between reinforcer delays versus choice between reinforcer magnitudes: Differential Fos expression in the orbital prefrontal cortex and nucleus accumbens core. Behavioural Brain Research, 2010, 213, 269-277.	2.2	28
82	Epistatic interaction of CREB1 and KCNJ6 on rumination and negative emotionality. European Neuropsychopharmacology, 2011, 21, 63-70.	0.7	28
83	Variability in the Effect of 5-HTTLPR on Depression in a Large European Population: The Role of Age, Symptom Profile, Type and Intensity of Life Stressors. PLoS ONE, 2015, 10, e0116316.	2.5	28
84	The effect of chronic fluvoxamine on hormonal and psychological responses to buspirone in normal volunteers. Psychopharmacology, 1996, 128, 74-82.	3.1	27
85	Neuronal Nitric Oxide Synthase (NOS1) Polymorphisms Interact with Financial Hardship to Affect Depression Risk. Neuropsychopharmacology, 2014, 39, 2857-2866.	5.4	26
86	Timeâ€dependent neuronal changes associated with craving in opioid dependence: an <scp>fMRI</scp> study. Addiction Biology, 2018, 23, 1168-1178.	2.6	26
87	Drug treatment of depression: reflections on the evidence. Advances in Psychiatric Treatment, 2003, 9, 11-20.	0.5	25
88	Detection of the acute effects of hydrocortisone in the hippocampus using pharmacological fMRI. European Neuropsychopharmacology, 2012, 22, 867-874.	0.7	25
89	Development and validation of the Generalized Anxiety Disorder Inventory (GADI). Journal of Psychopharmacology, 2007, 21, 145-152.	4.0	24
90	Rumination in migraine: Mediating effects of brooding and reflection between migraine and psychological distress. Psychology and Health, 2016, 31, 1481-1497.	2.2	24

#	Article	IF	Citations
91	Clozapine monotherapy for catatonic schizophrenia: should clozapine be the treatment of choice, with catatonia rather than psychosis as the main therapeutic index?. Journal of Psychopharmacology, 2005, 19, 432-433.	4.0	23
92	Distinct effects of folate pathway genes MTHFR and MTHFD1L on ruminative response style: a potential risk mechanism for depression. Translational Psychiatry, 2016, 6, e745-e745.	4.8	23
93	Effect of quinolinic acid-induced lesions of the subthalamic nucleus on performance on a progressive-ratio schedule of reinforcement: A quantitative analysis. Behavioural Brain Research, 2008, 195, 223-230.	2.2	21
94	TOMM40 rs2075650 May Represent a New Candidate Gene for Vulnerability to Major Depressive Disorder. Neuropsychopharmacology, 2014, 39, 1743-1753.	5.4	21
95	Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. Health Technology Assessment, 2018, 22, 1-136.	2.8	21
96	Variants in the <scp>CNR1</scp> gene predispose to headache with nausea in the presence of life stress. Genes, Brain and Behavior, 2017, 16, 384-393.	2.2	20
97	Metergoline abolishes the prolactin response to buspirone. Psychopharmacology, 1990, 100, 283-284.	3.1	18
98	Financial difficulties but not other types of recent negative life events show strong interactions with 5-HTTLPR genotype in the development of depressive symptoms. Translational Psychiatry, 2016, 6, e798-e798.	4.8	18
99	Quantitative analysis of the effect of lesions of the subthalamic nucleus on intertemporal choice: further evidence for enhancement of the incentive value of food reinforcers. Behavioural Pharmacology, 2009, 20, 437-446.	1.7	17
100	Managing inadequate antidepressant response in depressive illness. British Medical Bulletin, 2015, 115, 183-201.	6.9	17
101	Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness. Advances in Psychiatric Treatment, 2001, 7, 170-180.	0.5	16
102	Genetic variants in the catecholâ€oâ€methyltransferase gene are associated with impulsivity and executive function: Relevance for major depression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 928-940.	1.7	16
103	Information processing in anxiety: a pilot study of the effect of manipulating 5-HT function. Journal of Psychopharmacology, 1998, 12, 155-160.	4.0	15
104	Changes in the neural correlates of self-blame following mindfulness-based cognitive therapy in remitted depressed participants. Psychiatry Research - Neuroimaging, 2020, 304, 111152.	1.8	15
105	Treatment of bipolar affective disorder in clinical practice. Journal of Psychopharmacology, 2001, 15, 55-57.	4.0	14
106	Enhanced subgenual cingulate response to altruistic decisions in remitted major depressive disorder. NeuroImage: Clinical, 2014, 4, 701-710.	2.7	14
107	A new stress sensor and risk factor for suicide: the T allele of the functional genetic variant in the GABRA6 gene. Scientific Reports, 2017, 7, 12887.	3.3	14
108	Associations between childhood maltreatment and inflammatory markers. BJPsych Open, 2019, 5, e3.	0.7	14

#	Article	IF	Citations
109	Mirtazapine antagonises the subjective, hormonal and neuronal effects of m-chlorophenylpiperazine (mCPP) infusion: A pharmacological-challenge fMRI (phMRI) study. NeuroImage, 2011, 58, 497-507.	4.2	13
110	We all know what we mean by treatment-resistant depression â€“ don't we?. British Journal of Psychiatry, 2018, 212, 259-261.	2.8	13
111	A comparison of permutation and parametric testing for between group effective connectivity differences using DCM. NeuroImage, 2010, 50, 509-515.	4.2	12
112	Cognitive function after electroconvulsive therapy for depression: relationship to clinical response. Psychological Medicine, 2021, 51, 1647-1656.	4.5	12
113	Effect of moderate weight loss on prolactin secretion in normal female volunteers. Psychiatry Research, 1989, 29, 161-167.	3.3	11
114	The effect of moderate weight loss on overnight growth hormone and cortisol secretion in healthy female volunteers. Journal of Affective Disorders, 1989, 16, 197-202.	4.1	11
115	Management of diabetes mellitus occurring during treatment with olanzapine: report of six cases and clinical implications. Journal of Psychopharmacology, 2004, 18, 128-132.	4.0	11
116	NewMood: A productive European model of collaboration for translational research in depression. European Neuropsychopharmacology, 2011, 21, 1-2.	0.7	11
117	Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study). BMC Psychiatry, 2015, 15, 257.	2.6	11
118	CANMAT Guidelines for depression: Clear and user-friendly. Journal of Affective Disorders, 2009, 117, S3-S4.	4.1	10
119	Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial. Trials, 2016, 17, 66.	1.6	10
120	P2RX7 gene variation mediates the effect of childhood adversity and recent stress on the severity of depressive symptoms. PLoS ONE, 2021, 16, e0252766.	2.5	10
121	New approaches to treating resistant depression. BJ Psych Advances, 2015, 21, 315-323.	0.7	9
122	Cueing emotional memories during slow wave sleep modulates next-day activity in the orbitofrontal cortex and the amygdala. NeuroImage, 2022, 253, 119120.	4.2	9
123	Prolactin response to the dopamine antagonist, metoclopramide, in depression. Biological Psychiatry, 1991, 30, 313-316.	1.3	8
124	A meta-analysis of the efficacy of selective serotonin reuptake inhibitors compared to tricyclic antidepressants in depression. European Neuropsychopharmacology, 1994, 4, 332.	0.7	8
125	Changes in Pharmacological treatment for Bipolar Disorder Over Time in Manchester: A Comparison with Lloyd et al. (2003). Journal of Psychopharmacology, 2004, 18, 441-444.	4.0	8
126	Frontal haemodynamic responses in depression and the effect of electroconvulsive therapy. Journal of Psychopharmacology, 2019, 33, 1003-1014.	4.0	8

#	Article	IF	Citations
127	The new antidepressants. Current Anaesthesia and Critical Care, 1999, 10, 32-39.	0.3	7
128	Pharmacological Treatment of Unipolar Depression. Current Topics in Behavioral Neurosciences, 2012, 14, 263-289.	1.7	7
129	Study protocol for the randomised controlled trial: Antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study). BMC Psychiatry, 2013, 13, 205.	2.6	7
130	Prescribing antidepressants for depression: time to be dimensional and inclusive. British Journal of General Practice, 2011, 61, 50-52.	1.4	6
131	Prescribing for moderate or severe unipolar depression in patients under the long-term care of UK adult mental health services. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532093049.	2.7	6
132	Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study). Efficacy and Mechanism Evaluation, 2017, 4, 1-112.	0.7	6
133	Inflamed Mind: Multiple Genetic Variants of IL6 Influence Suicide Risk Phenotypes in Interaction With Early and Recent Adversities in a Linkage Disequilibrium-Based Clumping Analysis. Frontiers in Psychiatry, 2021, 12, 746206.	2.6	6
134	Commentary on â€˜Re-evaluation of the efficacy and tolerability of venlafaxine versus SSRI: meta-analysisâ€™ by Weinmann et al.. Psychopharmacology, 2008, 196, 521-522.	3.1	5
135	Spatiotemporal brain activation pattern following acute citalopram challenge is dose dependent and associated with neuroticism: A human phMRI study. Neuropharmacology, 2020, 170, 107807.	4.1	5
136	Positive Shifts in Emotion Evaluation Following Mindfulness-Based Cognitive Therapy (MBCT) in Remitted Depressed Participants. Mindfulness, 2021, 12, 623-635.	2.8	5
137	Randomised controlled trial of Antiglucocorticoid augmentation (metyrapone) of antiDepressants in Depression (ADD Study). Efficacy and Mechanism Evaluation, 2015, 2, 1-98.	0.7	5
138	â€œOut, out, brief candle! Lifeâ€™s but a walking shadowâ€¦ 5-HTTLPR Is Associated With Current Suicidal Ideation but Not With Previous Suicide Attempts and Interacts With Recent Relationship Problems. Frontiers in Psychiatry, 2020, 11, 567.	2.6	4
139	Electroconvulsive therapy (ECT) versus sham ECT for depression: do study limitations invalidate the evidence (and mean we should stop using ECT)?. BJ Psych Advances, 2021, 27, 285-291.	0.7	4
140	Commentary on STAR*D: a summary and UK perspective. Journal of Psychopharmacology, 2009, 23, 613-614.	4.0	2
141	Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial. Journal of Psychopharmacology, 2020, 34, 1342-1349.	4.0	2
142	An ongoing process of reconnection: A qualitative exploration of mindfulnessâ€based cognitive therapy for adults in remission from depression. Psychology and Psychotherapy: Theory, Research and Practice, 2022, 95, 173-190.	2.5	2
143	Drug Information Not Regulation is Needed. Journal of Psychopharmacology, 2004, 18, 14-15.	4.0	1
144	Making decisions in the absence of high quality clinical evidence: we need to bring some science into the judgement. Journal of Psychopharmacology, 2005, 19, 133-133.	4.0	1

#	Article	IF	Citations
145	Bad medicine or bad mouthing?. BMJ: British Medical Journal, 2011, 342, d3185-d3185.	2.3	1
146	Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression . ClinicoEconomics and Outcomes Research, 2019, Volume 11, 257-270.	1.9	1
147	BAP depression guidelines put antidepressant treatment in context. Progress in Neurology and Psychiatry, 2008, 12, 4-5.	0.9	0
148	No medication without representation? Generalizing from antidepressant clinical efficacy trials to clinical practice. Psychological Medicine, 2011, 41, 1349-1351.	4.5	0
149	Unipolar depression and dysthymia. Medicine, 2012, 40, 591-595.	0.4	0
150	Staying well has to be the main goal. BMJ, The, 2013, 346, f2307-f2307.	6.0	0
151	Nuevos enfoques para tratar la depresiÃ³n resistente [translation of â€œNew approaches to treating resistant depressionâ€•by Rodolfo Zaratiegui]. BJ Psych Advances, 2015, 21, .	0.7	0
152	Unipolar depressive disorders. Medicine, 2016, 44, 654-660.	0.4	0
153	Ketamine-ECT Study â€“ Author's reply. Lancet Psychiatry,the, 2017, 4, 662.	7.4	0
154	Does electroconvulsive therapy damage the brain?. Lancet Psychiatry,the, 2018, 5, 294-295.	7.4	0
155	Management of treatment nonresponse. , 2009, , 77-84.		0
156	Principles of therapy. , 2011, , 27-43.		0
157	Continuation and maintenance treatment. , 2011, , 85-90.		0
158	Principles of Therapy. , 2014, , 31-49.		0
159	Management of Treatment Nonresponse. , 2014, , 89-97.		0